预约演示
更新于：2025-02-08
Olaptesed Pegol
更新于：2025-02-08
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段临床1/2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
Sequence Code 29300655
来源: *****
关联
7
项与 Olaptesed Pegol 相关的临床试验NCT04901741
An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer Patients
The purpose of this study is to provide a go/no-go decision for a randomized expansion study by assessing the disease control rate (DCR) at 6 weeks for the combination of olaptesed pegol on top of pembrolizumab and (Arm 1) nanoliposomal irinotecan, 5-FU and leucovorin or (Arm 2) gemcitabine and nab-paclitaxel, to assess safety and tolerability and time-to-event endpoints.
开始日期2025-06-01 |
申办/合作机构 TME Pharma NV [+1] |
NCT04121455
Single-arm, Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a Multiple-arm Expansion Group
The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete tumor resection, and (ii) olaptesed pegol in combination with radiation therapy and bevacizumab in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete or complete tumor resection.
Further arms are included (i) to establish safety for the combination of olaptesed pegol at three different doses in addition to radiotherapy and bevacizumab, (ii) to explore the benefit of combining olaptesed pegol at different dose levels with bevacizumab in order to define the doses to move forward into a subsequent randomized dose-finding study, (iii) to explore the contribution of the therapy components olaptesed pegol and bevacizumab to patient benefit and (iv) to put the clinical outcome of these treatment regimens into perspective with the standard of care treatment with temozolomide and radiotherapy.
Further arms are included (i) to establish safety for the combination of olaptesed pegol at three different doses in addition to radiotherapy and bevacizumab, (ii) to explore the benefit of combining olaptesed pegol at different dose levels with bevacizumab in order to define the doses to move forward into a subsequent randomized dose-finding study, (iii) to explore the contribution of the therapy components olaptesed pegol and bevacizumab to patient benefit and (iv) to put the clinical outcome of these treatment regimens into perspective with the standard of care treatment with temozolomide and radiotherapy.
开始日期2019-09-12 |
申办/合作机构 |
NCT03168139
A Two-part, Open-label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic Cancer
The purpose of this study is to show that the type, number and/or distribution of tumor metastases infiltrating immune cells such as cytotoxic T cells and/or the cytokine signature in the tumor metastases can be modulated by treatment with olaptesed pegol and to explore safety, tolerability and efficacy of olaptesed pegol in combination with pembrolizumab as a basis for subsequent studies in combination with immunotherapies, in particular checkpoint inhibitors.
开始日期2017-04-18 |
申办/合作机构 TME Pharma NV [+1] |
100 项与 Olaptesed Pegol 相关的临床结果
登录后查看更多信息
100 项与 Olaptesed Pegol 相关的转化医学
登录后查看更多信息
100 项与 Olaptesed Pegol 相关的专利（医药）
登录后查看更多信息
38
项与 Olaptesed Pegol 相关的文献（医药）2022-04-01·European journal of pharmacology3区 · 医学
The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies
3区 · 医学
Review
作者: Mehrpouri, Mahdieh
C-X-C motif chemokine 12 (CXCL12), also known as stromal cell-derived factor-1 (SDF-1), is produced by the bone marrow microenvironment. This chemokine binds and activates its cognate receptors C-X-C chemokine receptor type 4 (CXCR4) and C-X-C chemokine receptor type 7 (CXCR7) to widely regulate cell proliferation, survival, differentiation, as well as homing and mobilization of hematopoietic stem cells (HSCs) in specialized niches within the bone marrow. Given this key role in hematopoiesis, it comes as no surprise that any aberrancies in CXCL12/CXCR4 or CXCL12/CXCR7 pathways might lead to excessive proliferation of HSCs, an event that leads to the development of leukemia. So far, numerous therapeutic interventions have been developed to harness CXCL12/CXCR4 and CXCL12/CXCR7 axes in leukemic cells. Plerixafor, BKT140, LY2510924, PF-06747143, ulocuplumab, and NOX-A12 are among the most well-known CXCR4 and CXCL12 modulators that their therapeutic efficacies have been evaluated in different pre-clinical and clinical studies of hematologic malignancies. To have an overview of the importance of CXCL12/CXCR4 and CXCL12/CXCR7 axes in the pathogenesis of leukemia and to gather information about the latest advances as well as challenges in targeting these axes in clinical settings, the present review has begun with a discussion about how aberrant expression of CXCL12/CXCR4 and CXCL12/CXCR7 pathways might regulate leukemogenesis and ended by outlining the key news of preclinical and clinical investigations in leukemia treatment.
2021-10-01·Journal for immunotherapy of cancer2区 · 医学
Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects
2区 · 医学
ArticleOA
作者: Beyer, Diana ; Mangasarian, Aram ; Eulberg, Dirk ; Jungelius, Jarf Ulf ; Hohmann, Nicolas ; Williams, Anja ; Frömming, Anna ; Jäger, Dirk ; Pruefer, Ulrike ; Halama, Niels ; Krauss, Jürgen ; Schreiber, Jutta ; Baumann, Matthias ; Suarez-Carmona, Meggy
Background:
Immunotherapy in microsatellite stable colorectal or pancreatic cancer has not shown promising results. It has been hypothesized that targeting immunosuppressive molecules like SDF1-alpha/CXCL12 could contribute to immunotherapy and animal models showed promising results on T cell activation and migration in combination with immune checkpoint inhibition.
Methods:
Here, we describe the successful application of anti-CXCL12 (NOX-A12) in patients with advanced stage pretreated metastatic colorectal and pancreatic cancer (OPERA trial). The treatment consisted of 2 weeks of anti-CXCL12 monotherapy with NOX-A12 followed by combination therapy with pembrolizumab (n=20 patients) until progression or intolerable toxicity had occurred.
Results:
The treatment was safe and well tolerated with 83.8% grade I/II, 15.5% grade III and 0.7% grade V adverse events. Of note, for a majority of patients, time on trial treatment was prolonged compared with their last standard treatment preceding trial participation. Systematic serial biopsies revealed distinct patterns of modulation. Tissue and clinical responses were associated with Th1-like tissue reactivity upon CXCL12 inhibition. A downregulation of a cytokine cassette of interleukin (IL)-2/IL-16/CXCL-10 was associated with tumor resistance and furthermore linked to a rare, CXCL12-associated CD14+CD15+promonocytic population. T cells showed aggregation and directed movement towards the tumor cells in responding tissues. Serum analyses detected homogeneous immunomodulatory patterns in all patients, regardless of tissue responses.
Conclusions:
We demonstrate that the combination of CXCL12 inhibition and checkpoint inhibition is safe and grants further exploration of synergistic combinatorial strategies.
2021-10-01·Analytica chimica acta2区 · 化学
Electrochemical detection of hepcidin based on spiegelmer and MoS2NF-GNR@AuNPs as sensing platform
2区 · 化学
Article
作者: Rana, Shilpa ; Kaur, Amandeep ; Bhatnagar, Archana ; Bharti, Anu ; Singh, Suman ; Prabhakar, Nirmal
Spiegelmers, mirror image L- RNA oligonucleotides, possesses high plasma stability and non-immunogenicity. Herein, a novel spiegelmer based impedimetric biosensor grafted with Au nanoparticles and molybdenum disulfide nanoflowers/graphene nanoribbons nanocomposite has been designed to detect hepcidin in spiked-in human serum sample. Firstly, molybdenum disulfide nanoflowers/graphene nanoribbons (MoS2NF-GNR) hybrid was drop-casted onto the FTO electrode followed by electro deposition of Au nanoparticles (AuNPs). Hepcidin specific thiolated spiegelmer was then immobilized on the MoS2NF-GNR@AuNPs for hepcidin detection. Electrochemical impedance spectroscopy was used to assess the performance of the sensing platform based on the variation of charge transfer resistance (ΔRct) relative to the Fe(CN)64-/3- electrochemical probe in the presence of hepcidin. The impedance signals were recorded at the frequency range of 10-1 to 105 Hz and potential was set as 0.18 V. Under optimized conditions, the limit of detection of spiegelmer based sensor for hepcidin was 0.173 pgmL-1 within a wide linear range of 0.005-10 ngmL-1. The biosensor possesses selectivity, acceptable reproducibility with RSD as 4.76% and stability for up to 20 days. The satisfactory recovery result (89.8-103.1 %) in human serum indicates that the sensor has applicability in clinical monitoring of hepcidin.
4
项与 Olaptesed Pegol 相关的新闻（医药）2024-07-17
BERLIN--(
BUSINESS WIRE
)--
TME Pharma N.V. (Euronext Growth Paris: ALTME),
a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that an abstract featuring results from the NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma) has been selected for presentation at the
European Society for Medical Oncology (ESMO) Congress
taking place in Barcelona, Spain, September 13-17, 2024.
The oral presentation will provide further analysis of the dual inhibition of NOX-A12 and bevacizumab in glioblastoma in the expansion arm of the GLORIA Phase 1/2 trial. The full abstract will be published online via the
ESMO Congress website
. 00:05 a.m. CEST on Monday, September 09, 2024. It will be available concurrently on the
TME Pharma
website.
Title:
Dual inhibition of postradiogenic angio-vasculogenesis in glioblastoma: Results of the phase 1/2 GLORIA trial
Presenter:
Dr.
Frank A. Giordano, Chair of the Department of Radiation Oncology, University Medical Center Mannheim, Germany
Session:
Mini oral session: CNS tumors
Time and Date:
08.30-8.35 a.m. CEST, Sunday, September 15, 2024
About TME Pharma
TME Pharma
is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company’s oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair.
临床研究放射疗法
2023-05-08
DUBLIN, May 8, 2023 /PRNewswire/ -- The "Pancreatic Cancer - Competitive landscape, 2023" report has been added to
ResearchAndMarkets.com's offering.
This "Pancreatic Cancer- Competitive landscape, 2023" report provides comprehensive insights about 250+ companies and 300+ drugs in Pancreatic Cancer Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In March 2023, Adaptimmune Therapeutics plc. and TCR Therapeutics Inc. (NASDAQ: TCRR), announced entry into a definitive agreement under which Adaptimmune will combine with TCR in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors.
The combination provides extensive benefits for clinical development and product delivery supported by complementary technology platforms. As a result, and following the closing of the transaction, it is anticipated that the combined company's cash runway will extend into 2026.
In February 2023, Akamis Bio, announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to include a clinical collaboration with the Cancer Research Institute (CRI) that will focus on advancing novel treatments for pancreatic cancer.
As part of the Akamis Bio, PICI, and CRI partnership, NG-350A, an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody, will be evaluated in combination with standard-of-care chemotherapy and the CTLA-4 inhibitor ipilimumab (YERVOY).
In February 2023, Gritstone bio, Inc. announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health, to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone's KRAS-directed vaccine candidate, SLATE-KRAS, in a Phase 1 study. Under the terms of the agreement, NCI will identify patients with metastatic cancer that are eligible for adoptive cell transfer based on the presence of a G12V or G12D KRAS mutation (KRASmut).
In February 2023, Keymed Biosciences Inc., jointly announced a global exclusive license agreement with AstraZeneca for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC). Under the license agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialization of CMG901 globally. CMG901 is currently in a Phase I clinical trial for the treatment of Claudin 18.2-positive solid tumors.
In January 2023, AIM ImmunoTech Inc. announced it has entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca. Under the agreement, Erasmus MC is planning to perform an investigator-initiated clinical study, entitled "Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy effect. DURIPANC Study," in which it will use both Study Drugs provided by AstraZeneca and AIM ImmunoTech.
Pancreatic Cancer Analytical Perspective
In-depth Commercial Assessment: Pancreatic Cancer Collaboration Analysis by Companies
The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Pancreatic Cancer drugs?
How many Pancreatic Cancer drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Pancreatic Cancer and their status?
What are the key designations that have been granted to the emerging and approved drugs?
Key Players
Panbela Therapeutics
ERYtech Pharma
Jiangsu HengRui Medicine Co., Ltd.
FibroGen
Novartis AG
AB Science
TME Pharma AG
Intensity Therapeutics
Silenseed LTD
SynerGene Therapeutics
Elevation oncology
Salspera LLC
Redx Pharma Plc
AIM ImmunoTech Inc.
Rain Oncology
Jazz Pharmaceuticals
Invyte Corporation
Immodulon Therapeutics Ltd
GSK plc
Merck Sharp & Dohme LLC
Roche
Helsinn Healthcare SA
Argenus Inc.
Actuate Therapeutics
OSE Immunotherapeutics
Incyte Corporation
Galera Therapeutics
CSPC ZhongQi Pharmaceutical Technology
Astellas Pharma Global Development, Inc.
NanOlogy
Theriva Biologics
AstraZeneca
Berg, LLC
Agenus
ABVC BioPharma, Inc.
Boehringer Ingelheim
Alligator Bioscience
CARsgenTherapeutics Co.,Ltd
Purple Biotech Ltd.
Lisata Therapeutics
Chongqing Precision Biotech Co., Ltd
Cybrexa Therapeutics
Bold Therapeutics
BioNTech SE
Bristol-Myers Squibb
DEKA Biosciences
Senhwa Biosciences
Cue Biopharma
Carisma Therapeutics Inc
Key Products
Olaptesed pegol
INT230-6
SBP-101
Masitinib
NIS793
siG12D LODER
SGT-53
Seribantumab
Salmonella-IL2
RXC004
Rintatolimod
RAIN-32
Lurbinectedin
Retifanlimab
IMM-101
GSK2256098
Belzutifan
Atezolizumab
Anamorelin
AGEN1423
Elraglusib
OSE2101
Epacadostat
GC4711
Docetaxel
Zolbetuximab
NanoPac
VCN-01
Danvatirsen
BPM31510
Botensilimab
ABV-1703
BI 907828
Mitazalimab
CT041
CM24
CEND-1
CEA-targeted CAR-T cells
CBX-12
BOLD-100
BNT141
BMS-813160
DK210
CX-5461
CUE-102
CT-0508
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo:
SOURCE Research and Markets
免疫疗法引进/卖出疫苗临床1期抗体药物偶联物
2023-05-01
The dynamics of the glioma market are anticipated to change in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage by key players, such as Bayer, VBL Therapeutics, Candel Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, and others
LAS VEGAS, May 1, 2023 /PRNewswire/ -- DelveInsight's
Glioma Market Insights report includes a comprehensive understanding of current treatment practices, glioma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Glioma Market Report
As per DelveInsight analysis, the glioma market size in the 7MM was approximately
USD 1 billion in 2022.
According to the assessment done by DelveInsight, the estimated total incident glioma cases in the 7MM were approximately
47K in 2022.
Leading glioma companies such as
Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, VBI Vaccines, TME Pharma, Day One Biopharmaceuticals, Servier, Orbus Therapeutics, TVAX Biomedical, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Forma Therapeutics, Hoffmann-La Roche, Incyte Corporation, Eli Lilly, and others are developing novel glioma drugs that can be available in the glioma market in the coming years.
The promising glioma therapies in the pipeline include
Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, Ofranergene Obadenovec (VB-111), LAM561 (2-OHOA), MEDI4736 (durvalumab), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), IGV-001, SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, SONALA-001 + Exablate 2.0 Device, VAL-083 (dianhydrogalactitol), Pomalidomide, MDNA55, BMX-001, Lenvatinib ± Pembrolizumab, Paxalisib (GDC-0084), OKN-007, Temferon, EO2401, INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Selinexor (KPT-330), Olutasidenib (FT-2102), VBI-1901, NOX-A12 (Olaptesed Pegol), Tovorafenib (DAY101), Vorasidenib (AG-881), Eflornithine, TVI-Brain-1, AB-218, BGB-290, Mirdametinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, Cobimetinib, PEMAZYRE (Pemigatinib), VERZENIO (abemaciclib)
, and others.
In
December 2022, Chimerix announced the successful launch of the ONC201 Phase III ACTION study in patients with H3 K27M-mutant glioma.
In
June 2022, Day One Biopharmaceuticals announced positive initial data from its pivotal Phase II (FIREFLY-1) study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG).
Discover which therapies are expected to grab the major glioma market share @
Glioma Market Report
Glioma Overview
Glioma is the most common kind of glial cell tumor in the central nervous system (CNS). Gliomas are infiltrative tumors that affect the brain tissue surrounding them. Glioblastoma is the most hazardous type of brain tumor, whereas pilocytic astrocytomas are the least dangerous. Previously, diffuse gliomas were classified into subgroups and grades depending on histopathologies, such as diffuse astrocytomas, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. The specific etiology of glioma, like other primary brain tumors, remains unknown. However, certain variables may increase the risk of getting a brain tumor. Glioma symptoms vary depending on tumor type, size, location, and growth rate. Some common glioma symptoms include headache, nausea or vomiting, memory loss, urine incontinence, speech problems, and others. A medical history and a physical examination are used for glioma diagnosis.
Glioma Epidemiology Segmentation
DelveInsight estimates that there were approximately
47K incident cases of glioma in the 7MM in 2022.
As per our analysis, the United States contributed to the largest incident population of glioma, acquiring
~40% of the 7MM in 2022.
The
glioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total glioma incident cases
Glioma grade-specific cases
Glioma age-specific cases
Glioma type-specific cases
Download the report to understand which factors are driving glioma epidemiology trends @
Glioma Epidemiological Insights
Glioma Treatment Market
Glioma treatment is based on the type of glioma, its size and location, and the patient's unique characteristics. Chemotherapy and radiation therapy will be administered after surgery, particularly in individuals when the tumor cannot be removed entirely because it has invaded critical parts of the brain or is inaccessible. The typical glioma treatment protocol comprises
surgery, chemotherapy, and radiation. Chemotherapy may include
carmustine (BCNU), lomustine (CCNU), or gleostine (generic), cisplatin, carboplatin, etoposide, and irinotecan in case of low-grade glioma whereas
temozolomide (TEMODAR) is the standard chemotherapy used in case of high-grade glioma majorly,
Gliadel wafer implants (biodegradable discs injected with BCNU) are usually given as adjunctive treatment after surgery, although usage of Gliadel wafers remains a point of controversy due to its questionable survival benefits.
Avastin (Genentech) and Temodar/Temodal (Merck), among others, are approved medications for HGG. However, due to patent expiration, the generic version of Temodar and biosimilars of
Avastin are available on the glioma market. As generics and biosimilars are more cost-effective for patients than new medicines, intense competition exists among them. Furthermore, due to a lack of knowledge concerning bevacizumab's overall survival benefit, it is not recommended in unselected patients with newly diagnosed GBM. Currently, only one medication for LGG is approved,
Tafinlar (dabrafenib) plus Mekinist (trametinib).
Moreover, the current therapeutic market lacks a viable method for curing glioblastoma; therefore, the survival rate of people diagnosed with glioma remains poor. Glioma is incurable, and treatment choices are limited. Furthermore, the tumor has a high recurrence rate and a poor patient prognosis. In addition, there is currently no approved therapy for the unmethylated MGMT patient pool.
To know more about glioma treatment guidelines, visit @
Glioma Management
Glioma Therapies and Key Companies
Regorafenib: Bayer
ONC201: Chimerix
AV-GBM-1: Aivita Biomedical
Enzastaurin (DB-102): Denovo Biopharma
DCVax-L: Northwest Therapeutics
Ofranergene Obadenovec (VB-111): VBL Therapeutics
LAM561 (2-OHOA): Laminar Pharmaceuticals
MEDI4736 (durvalumab): MedImmune
Tasadenoturev (DNX-2401): DNAtrix
ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
IGV-001: Imvax
SurVaxM: MimiVax
Berubicin: CNS Pharmaceuticals
GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)
Lerapolturev + Pembrolizumab: Istari Oncology
SONALA-001 + Exablate 2.0 Device: SonALAsense
VAL-083 (dianhydrogalactitol): Kintara Therapeutics
Pomalidomide: Bristol Myers Squibb
MDNA55: Medicenna Therapeutics
BMX-001: BioMimetix
Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme
Paxalisib (GDC-0084): Kazia Therapeutics
OKN-007: Oblato
Temferon: Genenta Science
EO2401: Enterome
INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals
Selinexor (KPT-330): Karyopharm Therapeutics
VBI-1901: VBI Vaccines
NOX-A12 (Olaptesed Pegol): TME Pharma
Tovorafenib (DAY101): Day One Biopharmaceuticals
Vorasidenib (AG-881): Servier
Eflornithine: Orbus Therapeutics
TVI-Brain-1: TVAX Biomedical
AB-218: AnHeart Therapeutics
BGB-290: Beigene
Mirdametinib: SpringWorks Therapeutics
FT-2102 (Olutasidenib): Forma Therapeutics
Vinblastine + Bevacizumab: Hoffmann-La Roche
Cobimetinib: Hoffmann-La Roche
PEMAZYRE (Pemigatinib): Incyte Corporation
VERZENIO (abemaciclib): Eli Lilly
Learn more about the FDA-approved drugs for glioma @
Drugs for Glioma Treatment
Glioma Market Dynamics
Glioma market growth can be ascribed to various factors, including an
aging population, evolving research, better diagnostic tests, developing surgical procedures, improved radiotherapy techniques, and novel systemic medicines.
Commercially, there is a
greater emphasis on high-grade glioma than low-grade glioma because patients with low-grade glioma often live longer than those with high-grade glioma. As a result, just a few
therapies are in late-stage studies, while the majority are in early-stage trials. In the case of GBM, on the other hand, the
pipeline is robust, with numerous potential therapies in late and mid-stage research that have yet to be marketed. The pipeline includes drugs with varied modes of action and administration routes. It is interesting to note that the emerging market of glioma includes budding gene therapy, i.e.,
ofranergene obadenovec (VB-111) by
VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as
VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), tasadenoturev (DNX-2401) by
VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively, and these therapies are going to alter the glioma market dynamics in the upcoming years.
The current glioma market has been categorized based on the dominant treatment pattern across the 7MM, which shows slight variances in the overall prescription pattern. The forecast model considers
surgery, chemotherapy/radiation therapy, bevacizumab + radiotherapy/chemotherapy, and OPTUNE with temozolomide. The
anticipated launch of new therapies and
improved integration of early patient screening,
medication in secondary care and other clinical settings,
research on optimum implementation methods, and
increased awareness may eventually facilitate the development of successful treatment alternatives.
However, there are a few challenges to the
timely identification and treatment of these patients, such as a
lack of a reliable biomarker that can aid in diagnosis and patient classification and
identifying recurrence and
signaling medication response. Furthermore, the
failure rate of high-phased drug trials is significant, making it impossible to predict trial success, exacerbating the need for medicines that could assist ease the patient segment with this severe kind of cancer.
Scope of the
Glioma
Market Report
Therapeutic Assessment: Glioma current marketed and emerging therapies
Glioma
Market Dynamics: Conjoint Analysis of Emerging Glioma Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's Views, Analyst's Views, Glioma Market Access and Reimbursement
Discover more about glioma drugs in development @
Glioma Clinical Trials
Table to Contents
Related Reports
Glioma Epidemiology Forecast
Glioma Epidemiology Forecast
– 2032 report delivers an in-depth understanding of the disease, historical and forecasted glioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Glioma Pipeline
Glioma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioma companies, including
PTC Therapeutics, Ono Pharmaceuticals, Philogen, SpringWorks Therapeutics, Xennials Therapeutics, AnHeart Therapeutics, Istari Oncology, among others.
High-Grade Glioma Pipeline
High-Grade Glioma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key high-grade glioma companies, including
PTC Therapeutics, Aadi, Lee's Pharmaceutical, among others.
Malignant Glioma Pipeline
Malignant Glioma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant glioma companies, including
Bexion Pharmaceuticals, Inc., Lee's Pharmaceutical Limited, Merck & Co, Oblato, Inc., OncoSynergy, Inc, among others.
Recurrent Malignant Glioma Pipeline
Recurrent Malignant Glioma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent malignant glioma companies, including
Bexion Pharmaceuticals, Inc., Merck, Oblato, OncoSynergy, Inc, among others.
Glioblastoma Pipeline
Glioblastoma Pipeline Insight
– 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioblastoma companies, including
AstraZeneca, BioNTech, Merck, Pfizer, Roche, among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market
| Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market
Related Healthcare Services
Healthcare Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP
临床3期临床2期疫苗免疫疗法
100 项与 Olaptesed Pegol 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胶质母细胞瘤 | 临床2期 | 德国 | 2019-09-12 | |
| 转移性结直肠癌 | 临床2期 | 德国 | 2017-04-18 | |
| 转移性胰腺癌 | 临床2期 | 德国 | 2017-04-18 | |
| 肿瘤转移 | 临床2期 | 德国 | 2017-04-18 | |
| 多发性骨髓瘤 | 临床2期 | 奥地利 | 2012-03-01 | |
| 多发性骨髓瘤 | 临床2期 | 法国 | 2012-03-01 | |
| 多发性骨髓瘤 | 临床2期 | 德国 | 2012-03-01 | |
| 多发性骨髓瘤 | 临床2期 | 意大利 | 2012-03-01 | |
| 复发性慢性淋巴细胞白血病 | 临床2期 | 奥地利 | 2012-03-01 | |
| 复发性慢性淋巴细胞白血病 | 临床2期 | 比利时 | 2012-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1/2期 | 25 | RT + NOX-A12 | 鹽艱顧鹹鹽夢願繭憲窪(夢蓋願繭繭艱醖鬱憲餘) = 繭獵簾窪艱網鹽夢鹽鑰 繭壓顧淵夢範製膚鬱遞 (夢觸獵繭鹹願遞糧構鑰, 4.7–18.4) 更多 | 积极 | 2023-05-31 | ||
RT + NOX-A12 (high EG12 score) | 淵選鑰積獵夢鹹選觸觸(觸壓顧網淵鑰鏇繭膚餘) = 獵壓齋觸蓋襯鏇壓遞構 觸蓋鏇鑰觸網鑰鑰醖糧 (糧壓糧艱獵鏇襯醖廠範 ) 更多 | ||||||
临床1/2期 | 胶质母细胞瘤 MGMT Promoter Methylation Negative | 6 | bevacizumab+NOX-A12 | 襯糧觸鬱廠艱壓鑰觸餘(糧膚獵選選製鹽醖衊齋) = Of all G ≥ 2 AEs (n = 37), two G2 events (5.4%) were deemed related to NOX-A12. 製壓廠獵鹽艱願鑰膚網 (鹽廠壓選選膚築製夢範 ) | 积极 | 2022-11-14 | |
临床1/2期 | - | Radiotherapy+NOX-A12 | 製積鏇鹽膚齋蓋積繭範(醖餘遞遞憲觸簾積壓醖) = 獵積網鹽膚選餘網鏇膚 淵鏇蓋繭積膚製衊獵鹽 (積醖築積鏇艱壓選夢鏇 ) 更多 | 积极 | 2022-06-05 | ||
Standard of Care | 積製窪壓鹽襯獵壓選範(願齋鬱膚憲遞壓壓鬱鹽) = 糧鹽遞淵構壓膚顧夢製 壓憲選範廠網廠衊繭夢 (積選膚遞醖醖糧餘繭鑰 ) 更多 | ||||||
临床1/2期 | 胶质母细胞瘤 MGMT | 10 | 廠艱網淵範襯醖蓋繭遞(壓艱構餘鬱獵簾構壓顧) = 鬱鏇選繭獵獵齋餘獵鏇 繭鏇衊憲膚窪繭簾艱觸 (膚積壓襯廠醖廠壓衊齋 ) 更多 | 积极 | 2022-06-02 | ||
临床1/2期 | 20 | 網壓膚夢憲鹽築廠鑰鑰(鬱願窪製醖鬱鹹鑰願襯) = The AE profile was comparable with the pembrolizumab profile and typical for the underlying diseases. 網築築繭襯鹽鑰積簾製 (糧夢繭蓋窪餘構網壓網 ) | 积极 | 2020-09-17 | |||
临床1/2期 | 20 | 膚醖壓窪廠夢選鹹廠鹽(廠構衊範廠鹹遞廠顧製) = 網顧遞觸齋衊鏇鏇觸鏇 構鹽鬱醖鹽衊顧壓廠範 (築醖襯艱積網餘築觸繭 ) 更多 | 积极 | 2020-08-15 | |||
临床2期 | 28 | bendamustine+rituximab+Olaptesed pegol | 鬱獵齋鑰蓋簾壓壓蓋衊(醖淵構糧鹽顧觸鹽齋鬱) = 顧廠糧鹹壓範獵繭艱夢 憲選願簾廠淵廠醖憲製 (積廠襯鹹繭廠繭網鏇願 ) 更多 | 积极 | 2019-10-01 | ||
临床1/2期 | 20 | 襯醖選鏇簾製糧艱醖淵(網淵選鏇蓋鑰網餘醖憲) = 膚鹹鑰積窪壓淵鑰積衊 淵觸願鹽鑰鹹夢範範夢 (獵齋鹽築築壓積繭構鏇 ) 更多 | 积极 | 2019-05-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用